Continued treatment with gefitinib (Iressa) beyond progression showed a trend toward better outcomes for those with T790M-negative non-small cell lung cancer (NSCLC).
Tony Mok, MD
Continued treatment with gefitinib (Iressa) beyond progression showed a trend toward better outcomes for those withT790M-negative non-small cell lung cancer (NSCLC), according to biomarker data from the phase III IMPRESS trial that was presented at this year’s World Conference on Lung Cancer (WCLC).1
In patients withT790M-negative NSCLC, median progression-free survival (PFS) was 6.7 months with gefitinib and 5.4 months with placebo, a nonsignificant difference (HR, 0.67; 95% CI, 043-1.03;P= .07). However, this lack of a statistically significant benefit could have resulted from the small number of patients included in the analysis, explained Tony Mok, MD.
In those withT790M-positive tumors, gefitinib was associated with a median PFS of 4.6 versus 5.3 months with placebo (HR, 0.97; 95% CI, 0.67-1.42;P= .88). For the full population of the study, PFS, overall survival (OS), objective response rate (ORR), and disease control did not differ significantly between patients who were treated with gefitinib and placebo.
“For patients who are plasma positive forT790Mat the time of RECIST progression, gefitinib should not be continued when platinum doublet chemotherapy is used as second-line therapy,” stated Mok, a professor of clinical oncology at the Chinese University of Hong Kong. “For patients who are plasma negative for T790Mat the time of RECIST progression, gefitinib in combination with doublet chemotherapy may offer clinical benefit that would require further confirmation in a prospective randomized study.”
EGFR TKIs are standard therapy for patients with EGFR-positive NSCLC. Almost all patients who initially respond to EGFR TKI therapy eventually develop resistance to the therapya result of theT790Mmutation in 50% to 60% of cases.
Optimal management for patients with acquired resistance to EGFR TKI therapy remains undetermined. Some evidence has suggested that continuation of EGFR TKI, in addition to platinum-containing chemotherapy at progression, may be beneficial because of potential tumor heterogeneity. The data are supported by retrospective clinical studies, said Mok.
The strategy of continuing EGFR TKI therapy at disease progression was evaluated for the first time in the phase III IMPRESS trial. The study consisted of 265 patients who were randomized to continue gefitinib plus platinum-based chemotherapy or chemotherapy alone at disease progression. Gefitinib was administered at 250 mg, cisplatin at 75 mg/m2, and pemetrexed at 500 mg/m2. PFS was the primary endpoint.
The molecular subgroup was explored using an investigational circulating tumor DNA biomarker analysis known as BEAMing. The analyses focused on predose levels ofT790M,L858R, and exon 19 deletionEGFRvariants. Blood samples were available for 98% of participants, with 54.4% testing T790M-positive and 40.2% returningT790M-negative.T790Mstatus was indeterminate in the remaining patients.
OS remained immature at 41% of the required events in theT790M-positive subgroup and 23% in theT790M-negative subgroup. In theT790M-positive group, the hazard ratio favored treatment with placebo over gefitinib (HR, 2.16,P= .0067). However, there was a slight trend toward a reduction in the risk of death with gefitinib in patients who haveT790M-negative tumors (HR, 0.83,P= .6644).
ORR did not differ significantly between treatment arms, according toT790Mstatus but showed a trend toward a higher response rate with gefitinib in the T790M-negative subgroup (37% vs 27.1%;P= .206). The disease control rate also was slightly better in the T790M-negative subgroup with gefitinib (93.5% vs 83.1%).
In addition to the molecular group, an extensive subgroup analysis of PFS did not show any significant differences between groups but generally showed trends in favor of the gefitinib arm. This analysis examined age, gender, region, time from progression, and prior responses to gefitinib.
“Patient testingby plasma and/or tumor—for theT790Mresistance mutation is warranted at RECIST progression following first-line EGFR tyrosine kinase inhibitor therapy, to best inform second-line treatment decisions,” Mok concluded.
For patients with theT790Mmutation, a variety of options are under exploration. Following progression on frontline EGFR inhibition, these third-generation inhibitors have demonstrated encouraging clinical benefit in patients with NSCLC.
In findings from the phase II AURA2 trial, also presented at WCLC, the ORR in patients withT790M-mutant NSCLC was 71% and the disease control rate was 92% with the third-generation TKI osimertinib (AZD9291).2Based off this study, and the phase II AURA trial, osimertinib received a priority review designation from the FDA as a treatment for patients with T790Malterations. The FDA will make a decision on the therapy in early 2016.
Click here for more articles:2015 World Conference on Lung Cancer> >